Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Pharmacotherapy for erectile dysfunction
Journal of Sexual Medicine, Volume 7, No. 1 PART 2, Year 2010
Notification
URL copied to clipboard!
Description
Introduction: Pharmacotherapy is the usual initial therapy for most men with erectile dysfunction. Aim: To review the current data relating to the efficacy, tolerability and safety of drugs used in the treatment of men with erectile dysfunction. Methods: A critical review of the literature relating to the use of pharmacotherapeutic agents was undertaken by a committee of eight experts from five countries, building on prior reviews. Main Outcome Measures: Expert opinion and recommendations were based on grading of evidence-based literature, internal committee dialogue, open presentation, and debate. Results: Almost all currently available evidence relates to sildenafil, tadalafil, and vardenafil. Phosphodiesterase type 5 (PDE5) inhibitors are first-line therapy for most men with erectile dysfunction who do not have a specific contraindication to their use. There is no evidence of significant differences in efficacy, safety, and tolerability between the PDE5 inhibitors and apomorphine. Intracavernosal injection therapy with alprostadil should be offered to patients as second line therapy for erectile dysfunction. Intraurethral alprostadil is a less effective treatment than intracavernosal alprostadil for the treatment of men with erectile dysfunction. Conclusions: PDE5 inhibitors are effective, safe, and well-tolerated therapies for the treatment of men with erectile dysfunction. Apomorphine, intracavernosal injection therapy with alprostadil, and intraurethral alprostadil are all effective and well-tolerated treatments for men with erectile dysfunction. We recommend some standardization of the assessment of psychosocial outcomes within clinical trials in the field of erectile dysfunction. © 2010 International Society for Sexual Medicine.
Authors & Co-Authors
Eardley, Ian
United Kingdom, Leeds
St James's University Hospital
Donatucci, Craig
United States, Durham
Duke University Medical Center
Corbin, Jackie
United States, Nashville
Vanderbilt University School of Medicine
El-Meliegy, Amr Ismail
Saudi Arabia, Jeddah
Dr Soliman Fakeeh Hospital
Hatzimouratidis, Kostas
Greece, Thessaloniki
Aristotle University of Thessaloniki
McVary, Kevin
United States, Evanston
Northwestern University
Munarriz, Ricardo
United States, Boston
Boston University
Lee, Sung Won
South Korea, Suwon
Skku School of Medicine
Statistics
Citations: 132
Authors: 8
Affiliations: 8
Identifiers
Doi:
10.1111/j.1743-6109.2009.01627.x
ISSN:
17436095
e-ISSN:
17436109
Research Areas
Health System And Policy
Sexual And Reproductive Health
Participants Gender
Male